KRAS and neoplasm: More importantly, since the combinatorial treatment showed inhibition of YAP1, we expect these drugs to show efficacy in K-Ras-independent PDAC tumors, where YAP1 is known to compromise for the loss of K-Ras to promote tumor growth.